Systematic pan-cancer analysis identifies transmembrane protein 158 as a potential therapeutic, prognostic and immunological biomarker

[1]  Shengchun Liu,et al.  Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer , 2022, BioMed research international.

[2]  Xiaohui Zeng,et al.  A transmembrane protein family gene signature for overall survival prediction in osteosarcoma , 2022, Frontiers in Genetics.

[3]  Haoran Li,et al.  TMEM158 Regulates the Canonical and Non-Canonical Pathways of TGF-β to Mediate EMT in Triple-Negative Breast Cancer , 2022, Journal of Cancer.

[4]  J. Ajani,et al.  Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis. , 2022, European journal of cancer.

[5]  Jamie L. Marshall,et al.  Single-nucleus cross-tissue molecular reference maps toward understanding disease gene function , 2022, Science.

[6]  C. Swanton,et al.  The translational challenges of precision oncology. , 2022, Cancer cell.

[7]  Vijaykumar Shivaji Gadekar,et al.  Multiple roles for basement membrane proteins in cancer progression and EMT. , 2022, European journal of cell biology.

[8]  Min Li,et al.  Targeted therapies for cancer , 2022, BMC Medicine.

[9]  Hao Zhang,et al.  TMEM158 promotes the proliferation and migration of glioma cells via STAT3 signaling in glioblastomas , 2022, Cancer Gene Therapy.

[10]  A. Leiser,et al.  Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers , 2021, ESMO open.

[11]  E. Nakakura,et al.  Discovering dominant tumor immune archetypes in a pan-cancer census , 2021, Cell.

[12]  S. Lui,et al.  Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis , 2021, Frontiers in Immunology.

[13]  R. Kalluri,et al.  Clinical and therapeutic relevance of cancer-associated fibroblasts , 2021, Nature Reviews Clinical Oncology.

[14]  Y. Kanai.  Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. , 2021, Pharmacology & therapeutics.

[15]  A. Kishan,et al.  Pan‐cancer analysis of prognostic metastatic phenotypes , 2021, International journal of cancer.

[16]  Hongmei Zhou,et al.  Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer , 2021, Signal Transduction and Targeted Therapy.

[17]  A. Buzdin,et al.  FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients , 2021, Frontiers in Oncology.

[18]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[19]  Donna M. Gress,et al.  Current and future cancer staging after neoadjuvant treatment for solid tumors , 2020, CA: a cancer journal for clinicians.

[20]  A. Stenzinger,et al.  Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. , 2020, Cancer discovery.

[21]  A. Goodman,et al.  The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. , 2020, Cancer cell.

[22]  Xi Huang,et al.  Ion Channels in Cancer: Orchestrators of Electrical Signaling and Cellular Crosstalk. , 2020, Reviews of physiology, biochemistry and pharmacology.

[23]  M. Simon,et al.  The tumor microenvironment , 2020, Current Biology.

[24]  Yoshiyuki Watanabe,et al.  Microsatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach , 2020, Archives of Toxicology.

[25]  D. Tuveson,et al.  DIVERSITY AND BIOLOGY OF CANCER-ASSOCIATED FIBROBLASTS. , 2020, Physiological reviews.

[26]  Xiaole Shirley Liu,et al.  TIMER2.0 for analysis of tumor-infiltrating immune cells , 2020, Nucleic Acids Res..

[27]  E. Sahai,et al.  SnapShot: Cancer-Associated Fibroblasts , 2020, Cell.

[28]  Hanyang Liu,et al.  TMEM158 promotes pancreatic cancer aggressiveness by activation of TGFβ1 and PI3K/AKT signaling pathway , 2020, Journal of cellular physiology.

[29]  E. Neilson,et al.  Origin and functional heterogeneity of fibroblasts , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  J. Wouters,et al.  Transmembrane (TMEM) protein family members: poorly characterized even if essential for the metastatic process. , 2020, Seminars in cancer biology.

[31]  A. McGuigan,et al.  The life cycle of cancer-associated fibroblasts within the tumour stroma and its importance in disease outcome , 2020, British Journal of Cancer.

[32]  Stephane E. Castel,et al.  Cell type–specific genetic regulation of gene expression across human tissues , 2019, Science.

[33]  Christopher D. Brown,et al.  The GTEx Consortium atlas of genetic regulatory effects across human tissues , 2019, Science.

[34]  P. Robson,et al.  Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. , 2019, Cancer discovery.

[35]  L. Shevde,et al.  The Tumor Microenvironment Innately Modulates Cancer Progression. , 2019, Cancer research.

[36]  J. Ross,et al.  Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Zemin Zhang,et al.  GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis , 2019, Nucleic Acids Res..

[38]  Yan Ding,et al.  CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer , 2019, Molecular Cancer.

[39]  R. Hegde,et al.  The Role of EMC during Membrane Protein Biogenesis. , 2019, Trends in cell biology.

[40]  C. Michiels,et al.  TMEM Proteins in Cancer: A Review , 2018, Front. Pharmacol..

[41]  T A Chan,et al.  Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[43]  Jun S. Liu,et al.  TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. , 2017, Cancer research.

[44]  Russell Bonneville,et al.  Landscape of Microsatellite Instability Across 39 Cancer Types. , 2017, JCO precision oncology.

[45]  F. Chang,et al.  Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[46]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[47]  Jay Shendure,et al.  Classification and characterization of microsatellite instability across 18 cancer types , 2016, Nature Medicine.

[48]  R. Kalluri.  The biology and function of fibroblasts in cancer , 2016, Nature Reviews Cancer.

[49]  Jun S. Liu,et al.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.

[50]  L. Zitvogel,et al.  Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  Umar Mahmood,et al.  Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. , 2015, Cancer cell.

[52]  N. Luo,et al.  Overexpression of TMEM158 contributes to ovarian carcinogenesis , 2015, Journal of experimental & clinical cancer research : CR.

[53]  E. Eisenhauer,et al.  Disease-free survival as an end-point in the treatment of solid tumours--perspectives from clinical trials and clinical practice. , 2014, European journal of cancer.

[54]  Umar Mahmood,et al.  Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. , 2014, Cancer cell.

[55]  Adam A. Margolin,et al.  Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas , 2013, Nature Genetics.

[56]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[57]  M. Ohtaki,et al.  TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells , 2012, Experimental lung research.

[58]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[59]  E. Carpenter,et al.  Overcoming the challenges of membrane protein crystallography , 2008, Current opinion in structural biology.

[60]  L. Daimiel,et al.  RIS1, a gene with trinucleotide repeats, is a target in the mutator pathway of colorectal carcinogenesis. , 2006, Cancer genetics and cytogenetics.

[61]  M. Gessler,et al.  Target genes of the WNT/β‐catenin pathway in Wilms tumors , 2006 .

[62]  M. Serrano,et al.  Analysis of the candidate tumor suppressor Ris-1 in primary human breast carcinomas. , 2006, Mutation research.

[63]  A. Puisieux,et al.  A twist for survival and cancer progression , 2005, British Journal of Cancer.

[64]  M. Serrano,et al.  Identification of a candidate tumor-suppressor gene specifically activated during Ras-induced senescence. , 2002, Experimental cell research.

[65]  W. Kuo,et al.  Extracellular Vesicles , 2017, Methods in Molecular Biology.

[66]  Norbert Graf,et al.  Target genes of the WNT/beta-catenin pathway in Wilms tumors. , 2006, Genes, chromosomes & cancer.